New Brunswick, N.J. – Puberty is a time in a girl’s life considered highly sensitive to stimulation by the hormone estrogen and a critical window during which estrogen exposure could greatly influence the risk of breast cancer later in life. An early onset of puberty also has been consistently shown in studies to increase the ...
Boehringer Ingelheim today announced the initiation of two phase II studies, 1200.89 and LUX-Breast 2, evaluating afatinib* in patients with metastatic breast cancer, who have an overexpression of the erbB2 (HER2) protein, so called HER2-positive patients. Afatinib* is an irreversible ErbB Family Blocker, which binds to all erbB-family kinases including erbB2 (HER2).1 The 1200.89 study ...
The development of monoclonal antibodies and other inhibitors of specific molecules, fully utilizing the insights learned from molecular techniques such as comparative microarrays and protein expression patterns, has led to the development and FDA approval of several agents for the treatment of breast cancer, such as trastuzamab (Herceptin, targeting HER-2 positive tumors) and lapatinib (Tykerb, ...
Breast cancer death rates have dropped over the last few years in Europe, however, researchers from France, Norway and the UK say this is due to better treatment and health systems rather than breast cancer screening. In an article in the BMJ (British Medical Journal), the authors wrote that “..breast cancer screening has not played ...
More breast cancer patients than previously believed may be receiving radiation treatments after breast-conserving surgery, a University of Michigan Comprehensive Cancer Center study shows. Researchers looked at a key database often used to assess whether cancer patients receive appropriate care and found that it may not always be adequately capturing whether breast cancer patients undergo ...
